Discover it Now!
The Prevention Committee was established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer. ESGO has set as its mission to improve the health and well-being of women with gynaecological cancers through prevention, research, excellence in care and education. The Prevention Committee is therefore one of the cornerstones to ensure the fulfilment of its mission.
The Chair of the Prevention Committee is Prof. Murat Gultekin.
Prevention Committee Chair: Murat Gultekin
Marc Arbyn, Esat Bilal, Nicolo Bizzarri, Sarah Bowden, Laia Bruni, Laura Burney Ellis, Kim Chatzistamatiou, Volkan Ege, Houssein El Hajj, Omar Gassama, Livia Giordano, Mihaela Grigore, Reda Hemida, Elmar Joura, Joana Kacperczyk-Bartnik, Vesna Kesic, Maria Kyrgiou, Belen Lopez, Anita Mitra, Nagham Ibraheem Mahdi, Afraa Mahjoob Al-Naddawi, Eva-Maria Niine-Roolaht, Patrick Petignat, Alejandra Picconi, Mario Preti, Zoia Razumova, Jalid Sehouli, Aleksandra Shavrova, Nadja Taumberger, Charalampos Theofanakis, Icó Tóth, Andreas Ullrich, Alexandra Wagner, Ignacio Zapardiel
We are preparing three webinars for you, save the date to your calendar!
Click here to register for free.
Ovarian cancers are among the most common gynaecological cancers among females. Despite the advances in treatment, the survival rates are still far away from our expectations. On the other hand, there is important scientific evidence accumulated in both carcinogenesis and the genetical background of these cancers and there is now a possibility to prevent these cancers using genetic screening, defining the risk of lifetime cancer development, and using either chemical or surgical prophylaxis to those high-risk populations. This webinar will summarize the existing evidence from the most well-known European experts.
Prof. Ranjit Manchanda (UK)
Dr. Claudia Marchetti (Italy)
Dr. Eric Leblanc (France)
Prof. Murat Gultekin (Turkey)
Prof. Maria Kyrgiou (UK)
This webinar is offered to you for free within the commitment of ESGO Prevention to provide premium educational contact. All you have to do is register here.
Speakers will be defined soon, you may already register here.
All Prevention Committee webinars are available on the eAcademy portal
Click on the link to see them all.
For recordings go to the ESGO eAcademy portal. You need to register to access it.
For recordings go to ESGO eAcademy portal. You need to register to access.
For recordings please go to the ENGAGe YouTube channel.
vulvar lesions, M. Preti, published as a joint publication in IJGC and LJGTD, June 2022
treatment for cervical intra-epithelial neoplasia and early invasive cervical cancer, M. Kyrgiou Accepted for publication in Lancet Oncology.
vulvar and vaginal disease, M. Preti (Accepted as joint publication in IJGC and LJGTD).
World Health Organization has launched ''Cervical Cancer Elimination Program'' on November 19, 2020.
The program asks the countries to vaccinate the girls under 15 years of age (90% coverage), to screen females by minimal two times when they are 35 and 45 (70%) coverage and to treat the lesions detected appropriately (in 90% of cases).
Modelling studies show that if all countries can implement the program until 2030 and can achieve these targets, there will be a 30% reduction in cervical cancer mortality by 2030 and the cervical cancer may be eliminated until the end of this century (namely incidence less than 4 \ 100.000).
ESGO Prevention committee has joined in to fulfil the WHO cervical cancer elimination strategy as a leading European actor in prevention.
RISCC: Risk-based Screening for Cervical Cancer
ESGO/ENGAGe is involved in the Horizon 2020 RISCC project.
Within the RISCC project ESGO / ENGAGe is responsible for the co-creation of the e-health/m-health platform for risk based cervical cancer screening and for the dissemination of the results to 12 ENGAGe member countries. This project is planned for five years and intended to terminate in 2025.
For more information about the ESGO/ENGAGe involvement please use the following link.
Dr. Murat Gultekin was awarded the IGCS Distinguished Advocacy Award for his extensive and tireless efforts to unify advocacy NGOs throughout Europe, forming ENGAGe. As the leading founder of HPV DNA Screening, Mobile Trucks and Central Mammography Report Unit, cancer registry systems and community- based palliative care system he is partly responsible for major innovations in cancer screening in Turkey and around the world. For more info visit the IGCS website.
Find out more